Q32 Bio

Yahoo Finance • 2 months ago

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as... Full story

Yahoo Finance • 4 months ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Direct Digital Holdings Inc. 237,043,770 0.1799 0.1469 0.1501 +0.0349 Q3... Full story

Yahoo Finance • 4 months ago

Akebia Announces Establishment of Rare Kidney Disease Pipeline

Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2 trial of Praliciguat... Full story

Yahoo Finance • 5 months ago

Q32 Bio GAAP EPS of -$0.60 beats by $0.59

* Q32 Bio press release [https://seekingalpha.com/pr/20305704-q32-bio-reports-third-quarter-2025-financial-results-and-provides-corporate-update] (QTTB [https://seekingalpha.com/symbol/QTTB]): Q3 GAAP EPS of -$0.60 beats by $0.59. * Ca... Full story

Yahoo Finance • 6 months ago

Healthcare Rally: Pulmonx, UHS, And X4 Lead After-Hours Gains Amid Strategic Updates

(RTTNews) - Several healthcare and biotech stocks posted notable gains in after-hours trading on Monday, driven by earnings updates, executive appointments, and capital market activity. Pulmonx Corp. (LUNG) surged 33.33% to $2.08 as of 9:... Full story

Yahoo Finance • 8 months ago

Q32 Bio August 2025 slides: Bempikibart shows durable response in alopecia areata

Introduction & Market Context Q32 Bio Inc (NASDAQ:QTTB) presented its corporate overview in August 2025, highlighting the company’s focus on immune therapeutics with a primary emphasis on its lead candidate Bempikibart for alopecia areata... Full story

Yahoo Finance • 10 months ago

Q32 Bio names interim chief medical officer

* Clinical-stage biotechnology company Q32 Bio (NASDAQ:QTTB [https://seekingalpha.com/symbol/QTTB]) appointed [https://seekingalpha.com/pr/20147073-q32-bio-appoints-adrien-sipos-m-d-ph-d-as-interim-chief-medical-officer] Adrien Sipos,... Full story